注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
RAPT Therapeutics Inc是一家臨床階段的基於免疫學的生物製藥公司。該公司專注於為炎症性疾病和腫瘤學需求未得到滿足的患者發現、開發和商業化口服小分子療法。該公司利用其藥物發現和開發引擎開發選擇性小分子,旨在調節這些疾病背後的關鍵免疫反應。它的兩種主要候選藥物均針對C-C基序趨化因子受體4 (CCR4)。其炎症候選藥物RPT193旨在選擇性抑制2型T輔助細胞(Th2細胞)遷移到發炎組織中。其主要的腫瘤候選藥物FLX475旨在選擇性地抑制免疫抑制性調節性T細胞 (Treg) 遷移到腫瘤中。此外,RPT193在特應性皮炎(AD)以外的多種炎症性疾病中具有臨床可轉化性,包括過敏性哮喘和慢性鼻竇炎。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Brian Russell Wong | 49 | 2015 | CEO, President & Director |
Linda Kozick | 64 | 2016 | Independent Director |
William J. Rieflin | 61 | 2015 | Independent Chairman of the Board |
Michael F. Giordano | 63 | 2018 | Independent Director |
Alexander Rudensky | - | - | Chairman of Scientific Advisory Board |
David V. Goeddel | 69 | 2015 | Member of Scientific Advisory Board |
Drew Mark Pardoll | - | 2017 | Member of Scientific Advisory Board |
Antoni Ribas | 54 | - | Member of Scientific Advisory Board |
Robert Zamboni | - | - | Member of Scientific Advisory Board |
Scott Joseph Antonia | - | 2017 | Member of Scientific Advisory Board |
Emma Guttman-Yassky | - | 2019 | Member of Scientific Advisory Board |
Philip D. Greenberg | - | 2017 | Member of Scientific Advisory Board |
Wendye Robbins | 60 | 2019 | Independent Director |
Mary Ann Gray | 69 | 2019 | Independent Director |
Lori M. Lyons-Williams | 46 | 2021 | Independent Director |
Lawrence Fong | - | 2020 | Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核